Bromocriptine in polycystic ovarian disease: a controlled clinical trial.
Bromocriptine and placebo were given to a group of 20 polycystic ovarian disease patients on a double-blind, cross-over basis. Patients were studied for three cycles: a baseline cycle without any medication, a placebo-treated cycle, and a bromocriptine-treated cycle with multiple plasma samples taken during the different phases of the menstrual cycle. The clinical response to bromocriptine was compared with that of a placebo for the following hormones: prolactin (PRL), luteinizing hormone (LH)/follicle-stimulating hormone (FSH) ratio, testosterone, androstenedione, estradiol-17 beta (E2), estrone (E1), and progesterone. Patients were divided into two subgroups: hyperprolactinemic (basal PRL greater than 20 ng/mL) and normoprolactinemic (basal PRL less than 20 ng/mL), and the response of both subgroups to bromocriptine was compared. Prolactin, LH/FSH ratio, testosterone, and E1 showed a significant drop with bromocriptine, whereas E2 significantly increased. Two out of nine amenorrheic polycystic ovarian disease patients menstruated during bromocriptine treatment, and three patients showed evidence of ovulation.
el Tabbakh
G H
GH
Department of Obstetrics and Gynecology, Alexandria Medical School, Egypt.
Loutfi
I A
IA
Azab
I
I
Rahman
H A
HA
Southren
A L
AL
Aleem
F A
FA
D000293:Adolescent; D000328:Adult; D000568:Amenorrhea / Q000150:complications / Q000503:physiopathology; D001971:Bromocriptine / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D012739:Gonadal Steroid Hormones / Q000097:blood; D006801:Humans; D008598:Menstruation; D010060:Ovulation; D011085:Polycystic Ovary Syndrome / Q000097:blood / Q000150:complications / Q000188:drug therapy*
D012739:Gonadal Steroid Hormones; D001971:Bromocriptine